4 results about "Esomeprazole" patented technology

The invention relates to a preparation method and application of 5-(1H-pyrrole-1-yl)-2-mercaptobenzimidazole, according to the preparation method, key parameters such as an ester extraction solvent, a pH adjusting range, a pulping solvent, a ratio of a concentrated solution to the pulping solvent and the like are determined to cooperate with each other, and efficient separation and purification of a product are realized. And the synergistic improvement of economy, environmental protection, high yield and high content is realized. The solvents and reagents selected in the whole process are conventional chemical raw materials, are low in price and easy to obtain, and the solvents and mother liquor can be recycled and reused, so that the production cost is further reduced; the operation process is simplified, the production cost and the environmental protection pressure are reduced, and the environmental protection requirement of industrial production is met; the yield of the target product can be stably kept at 74% or above, the purity can reach 99% or above, and the content is higher than 97%. The prepared product can be applied to preparation of ilaprazole, meets the quality requirement for preparation of qualified ilaprazole bulk drugs, and has important industrial application value.

Embodiments herein provide a pharmaceutical formulation comprising an anti-inflammatory antipyretic agent with reduced side effects, addressing gastric problems. An enteric-coated tablet of the present invention comprises esomeprazole, aceclofenac, and paracetamol, along with maize starch, microcrystalline cellulose, povidone K30, colloidal anhydrous silica, and magnesium stearate.

The application provides a preparation method of crystalline form B of ilaprazole. The application provides a preparation method of crystalline form B of ilaprazole, which comprises the following steps: mixing a solution or slurry of ilaprazole raw materials and a good solvent with an anti-solvent, and crystallizing to obtain the crystalline form B of ilaprazole. The preparation method of the application has the advantages of good stability, high yield, good purity, low solvent residue, compliance with the standard of raw materials, and suitability for industrial production.

The embodiment of the invention provides an application of a proton pump inhibitor or a derivative thereof, or a compound thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof in preparation of anti-xerophthalmia drugs. The proton pump inhibitor is prepared from any one or a combination of at least two of omeprazole, lansoprazole, pantoprazole, rabeprazole, reminoprazole, esomeprazole or tenatoprazole. According to the application, the proton pump inhibitor is loaded on the self-assembled nucleic acid, so that the composite material has efficient corneal cell membrane penetrating capacity, and can remarkably inhibit expression of inflammatory factors and improve the ocular surface inflammation microenvironment; in addition, the compound also has relatively good biological safety, shows an excellent treatment effect on in-vivo and in-vitro xerophthalmia models, and provides a new choice for clinical xerophthalmia treatment.